BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Financials Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.03 CNY | -5.75% |
|
-9.67% | -32.97% |
| May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
| Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 9,048 | 4,349 | 2,975 | - | - |
| Enterprise Value (EV) 1 | 8,836 | 4,475 | 3,108 | 2,911 | 2,569 |
| P/E ratio | -14.3 x | -11.3 x | -33.9 x | 31 x | 16.2 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 16.9 x | 6.07 x | 3.24 x | 2.6 x | 2.15 x |
| EV / Revenue | 16.6 x | 6.24 x | 3.38 x | 2.54 x | 1.86 x |
| EV / EBITDA | -19.8 x | -33.1 x | 37.4 x | 11.5 x | 5.65 x |
| EV / FCF | -16,257,344 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | 7.89 x | - | - | - | - |
| Nbr of stocks (in thousands) | 399,398 | 399,398 | 399,398 | - | - |
| Reference price 2 | 22.65 | 10.89 | 7.449 | 7.449 | 7.449 |
| Announcement Date | 3/27/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 354.6 | 533.9 | 716.9 | 919.3 | 1,145 | 1,383 |
| EBITDA 1 | - | -447 | -135.1 | 83.06 | 252.4 | 454.8 |
| EBIT 1 | - | -621.1 | -317.4 | -98.43 | 94.9 | 250.7 |
| Operating Margin | - | -116.33% | -44.28% | -10.71% | 8.29% | 18.14% |
| Earnings before Tax (EBT) 1 | - | -601.4 | -380.2 | -89 | 115 | 214 |
| Net income 1 | -545.6 | -601.9 | -383 | -89 | 98 | 182 |
| Net margin | -153.88% | -112.75% | -53.42% | -9.68% | 8.56% | 13.16% |
| EPS 2 | - | -1.580 | -0.9600 | -0.2200 | 0.2400 | 0.4600 |
| Free Cash Flow | - | -543.5 | - | - | - | - |
| FCF margin | - | -101.81% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 8/19/22 | 3/27/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 304.8 | 326.8 | 390.1 | 396.5 | 527 |
| EBITDA | - | - | - | - | - |
| EBIT | -328.4 | - | -157.8 | - | - |
| Operating Margin | -107.75% | - | -40.45% | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/27/23 | 9/26/23 | 3/27/24 | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 126 | 133 | - | - |
| Net Cash position 1 | - | 211 | - | - | 64.3 | 406 |
| Leverage (Debt/EBITDA) | - | - | -0.9358 x | 1.606 x | - | - |
| Free Cash Flow | - | -544 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -50.3% | - | -12.7% | 12.3% | 18.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | 2.870 | - | - | - | - |
| Cash Flow per Share | - | -0.8000 | - | - | - | - |
| Capex 1 | - | 240 | - | - | - | - |
| Capex / Sales | - | 45% | - | - | - | - |
| Announcement Date | 8/19/22 | 3/27/23 | 3/27/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.449
CNY
Average target price
14.21
CNY
Spread / Average Target
+90.82%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.97% | 411M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- 2315 Stock
- Financials Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
